Commitment to Investor
Kelyniam Global (OTC:KLYG), a manufacturer of custom cranial and craniofacial implants, has achieved an uplisting to the OTCID market tier on the OTC Markets Group platform. This upgrade reflects the company's commitment to transparency and compliance with financial reporting requirements.
The OTCID status distinguishes KLYG among OTC companies, requiring regular financial reporting and compliance with strict criteria. CFO Terrance Kurtenbach highlighted that this achievement could attract a broader investor base while supporting long-term growth. The company continues to focus on expanding its product portfolio, including PEEK cranial implants with patented fixation and regenerative products.
Kelyniam Global (OTC:KLYG), produttore di impianti cranici e craniofacciali su misura, 猫 stato promosso al livello OTCID sulla piattaforma OTC Markets Group. Questo passaggio testimonia l'impegno dell'azienda verso maggiore trasparenza e il rispetto degli obblighi di rendicontazione finanziaria.
Lo status OTCID distingue KLYG tra le societ脿 OTC imponendo report finanziari periodici e l'osservanza di rigorosi requisiti. Il CFO Terrance Kurtenbach ha sottolineato come questa conquista possa attirare una platea pi霉 ampia di investitori e sostenere la crescita a lungo termine. L'azienda prosegue nell'ampliamento del portafoglio prodotti, includendo impianti cranici in PEEK con fissazione brevettata e soluzioni rigenerative.
Kelyniam Global (OTC:KLYG), fabricante de implantes craneales y craneofaciales a medida, ha logrado ascender al nivel OTCID en la plataforma OTC Markets Group. Esta mejora refleja el compromiso de la compa帽铆a con la transparencia y el cumplimiento de los requisitos de informaci贸n financiera.
El estatus OTCID diferencia a KLYG entre las empresas OTC al exigir informes financieros peri贸dicos y el cumplimiento de criterios estrictos. El CFO Terrance Kurtenbach se帽al贸 que este logro podr铆a atraer a una base de inversores m谩s amplia y respaldar el crecimiento a largo plazo. La compa帽铆a sigue centrada en ampliar su cartera de productos, incluidos implantes craneales de PEEK con fijaci贸n patentada y productos regenerativos.
Kelyniam Global (OTC:KLYG)電� 毵烄钉順� 霊愱皽瓿冯憪臧滌晥氅� 鞛勴攲霝�韸鸽ゼ 鞝滌“頃橂姅 旮办梾鞙茧, OTC Markets Group 頂岆灚韽检棎靹� OTCID 鞁滌灔 霌标笁鞙茧 靸來枼 臁办爼霅橃棃鞀惦媹雼�. 鞚措矆 霌标笁 靸侅姽鞚� 鞛氤搓碃 鞖旉惮靷暛 欷�靾橃檧 韴獏靹膘棎 雽�頃� 須岇偓鞚� 鞚橃毳� 氚橃榿頃╇媹雼�.
OTCID 歆�鞙勲姅 KLYG毳� 雼るジ OTC 旮办梾霌り臣 甑秳頃橂┌ 鞝曣赴鞝侅澑 鞛 氤搓碃鞕� 鞐勱博頃� 旮办 欷�靾橂ゼ 鞖旉惮頃╇媹雼�. CFO 韰岆瀫鞀� 旎ろ厫氚旐潗(Terrance Kurtenbach)電� 鞚� 靹标臣臧� 雿� 雱撿潃 韴瀽鞛愳傅鞚� 鞙犾箻頃橁碃 鞛リ赴 靹膘灔鞐� 旮办棳頃� 靾� 鞛堧嫟瓿� 臧曥“頄堨姷雼堧嫟. 須岇偓電� 韸鬼棃 瓿犾爼 鞛レ箻臧� 鞝侅毄霅� PEEK 霊愱皽瓿� 鞛勴攲霝�韸胳檧 鞛儩 鞝滍拡鞚� 韽暔頃� 鞝滍拡 韽姼韽措Μ鞓� 頇曥灔鞐� 瓿勳啀 欤茧牓頃橁碃 鞛堨姷雼堧嫟.
Kelyniam Global (OTC:KLYG), fabricant d'implants cr芒niens et cranio-faciaux sur mesure, a 茅t茅 promu au niveau OTCID sur la plateforme OTC Markets Group. Cette mont茅e en gamme refl猫te l'engagement de la soci茅t茅 en faveur de la transparence et du respect des obligations de reporting financier.
Le statut OTCID distingue KLYG au sein des soci茅t茅s OTC en exigeant des rapports financiers r茅guliers et le respect de crit猫res stricts. Le directeur financier Terrance Kurtenbach a soulign茅 que cette r茅ussite pourrait attirer une base d'investisseurs plus large tout en soutenant la croissance 脿 long terme. L'entreprise continue de se concentrer sur l'茅largissement de son portefeuille de produits, incluant des implants cr芒niens en PEEK 脿 fixation brevet茅e et des produits r茅g茅n茅ratifs.
Kelyniam Global (OTC:KLYG), ein Hersteller kundenspezifischer kranialer und kraniofazialer Implantate, wurde in die OTCID-Marktklasse auf der OTC Markets Group-Plattform hochgestuft. Diese Aufwertung zeigt das Engagement des Unternehmens f眉r Transparenz und die Einhaltung finanzieller Berichtspflichten.
Der OTCID-Status hebt KLYG unter OTC-Unternehmen hervor und erfordert regelm盲脽ige Finanzberichte sowie die Erf眉llung strenger Kriterien. CFO Terrance Kurtenbach betonte, dass dieser Meilenstein eine breitere Investorenbasis anziehen und das langfristige Wachstum unterst眉tzen k枚nne. Das Unternehmen konzentriert sich weiterhin auf den Ausbau seines Produktportfolios, darunter PEEK-Kranialimplantate mit patentierter Befestigung und regenerative Produkte.
- Uplisting to OTCID tier demonstrates enhanced transparency and compliance
- Potential to attract broader investor base through improved market visibility
- Maintains ongoing reporting obligations, fostering greater investor confidence
- None.
Excellence Kelyniam Global, Inc. Uplists to OTCID Market Tier
Terrance Kurtenbach, Chief聽 Financial Officer of Kelyniam said, "Only a select group of OTC companies qualify for OTCID status, as it demands regular financial reporting and compliance with OTC Markets' criteria鈥攁 level of rigor that many OTC-listed entities do not meet. This distinction positions Kelyniam among a more transparent subset of the OTC ecosystem, potentially attracting a broader investor base and supporting long-term growth.
"We are 聽very excited 聽to have our shares moved to the elevated OTCID trading platform", This achievement not only validates our operational discipline but also enhances our ability to communicate effectively with the investment community as we continue to innovate in the custom cranial implant space."
"Unlike non-reporting tiers like Pink No Information or Expert Market, OTCID companies must maintain ongoing reporting obligations, including timely disclosures of financial statements and material events, which fosters greater investor confidence and facilitates more efficient trading. We applaud OTC Markets continued efforts to distinguish and elevated registrants with viable business operating models and robust governance and reporting standards in providing investors with reliable information and opportunity"
Kelyniam Global, Inc. remains focused on expanding its product portfolio, including its PEEK cranial implants with patented fixation, and regenerative products that include CustomizedBone漏聽(hydroxy apatite) implants and the Osteopore line of implants.
About Kelyniam Global, Inc. Kelyniam Global, Inc. specializes in the rapid production of custom cranial and craniofacial implants made from PEEK, a biocompatible polymer. The Company collaborates with neurosurgeons worldwide to deliver high-quality, patient-specific implants with a turnaround time of 48 hours. Kelyniam is committed to advancing medical technology and improving patient outcomes through innovation and precision manufacturing. For more information, visit .
Forward-Looking Statements聽This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Investors are cautioned not to place undue reliance on these forward-looking statements.
View original content:
SOURCE Kelyniam Global Inc
FAQ
What does Kelyniam Global's uplisting to OTCID mean for investors?
What are the requirements for Kelyniam (KLYG) to maintain OTCID status?
What products does Kelyniam Global (KLYG) manufacture?
How does OTCID status differ from other OTC market tiers?
